Press Release
Laurus Labs receives USFDA approval for Metformin Hydrochloride Tablets USP
Hyderabad, August 29, 2018, Laurus Labs Ltd. (Laurus BSE: 540222, NSE: Lauruslabs, ISIN: INE947Q01010)
Laurus Labs is pleased to announce that the Company has received an approval from United States Food and Drug Administration (US FDA) for Metformin Hydrochloride Tablets USP 500mg, 850mg and 1000mg which are used for treatment of diabetes.
Metformin Hydrochloride Tablets USP 500mg, 850mg, and 1000mg are therapeutically equivalent to Glucophage Tablets 500mg, 850mg, and 1000 mg of Bristol-Myers Squibb Company.
The Product and API will be commercialized from Companys Unit 2 located at APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.
Ask Value Research 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
